New paper from PHRI.ca Population Health Research Institute 🇨🇦 - Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial academic.oup.com/ehjcvp/advance… #CardioTwitter

#ResearchLetter: Rivaroxaban 2.5 mg twice daily plus aspirin reduces venous thromboembolism in patients with chronic atherosclerosis PHRI.ca Population Health Research Institute 🇨🇦 #AHAJournals ahajrnls.org/39QLrgb

More benefits noted in the COMPASS trial - reductions in venous thromboembolism as well. Now in Circulation. PHRI.ca Population Health Research Institute 🇨🇦 Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis ahajournals.org/doi/10.1161/CI…

We have reached a new milestone! Over 400 participants randomised in The TRACK Trial. Strong recruitment record in Malaysia led by Lily Mushahar; India by Raja Ramachandran (राजा) Dr Prof Manisha Sahay Dr Vinay Rathore; Saudi Arabia by Mohammed Hadi and Ahmed Shaman

Congratulations to all Malaysian investigators and coordinators for randomising 200 participants from Malaysia in The TRACK Trial Under the leadership of Dr Lily Mushahar Malaysia is leading the recruitment.

Happy 75th Independence Day to all our dedicated investigators and coordinators from India 🇮🇳

Today's #NephGR at uOttawa | Faculté de médecine, Faculty of Medicine and The Ottawa Hospital will be on the topic of 'Anti-thrombotic targets in advanced stages of kidney disease' from Sunil Badve of the The George Institute for Global Health The TRACK Trial

Do you want to know more about The TRACK Trial ? Watch this video to understand why is this trial so important for patients with advanced stages of CKD and kidney failure.

Grand succès pour la mise en place de l'étude The TRACK Trial en collaboration avec le The George Institute for Global Health , le CHRU de Nancy et @INICRCT !